To overcome these unwanted side effects, studies focused on TFEB, a down-stream target of mTOR, and showed that TFEB overexpression promoted the clearance of pathologic α-synuclein and restored neurodegeneration in PD animal models (Dehay et al., 2010; Decressac et al., 2013). This evidence concerns the gene TFEB and Parkinson disease.